[go: up one dir, main page]

MX2019002562A - Métodos para tratar cáncer que expresa la proteína del ligando 1 de muerte celular programada (pd-l1). - Google Patents

Métodos para tratar cáncer que expresa la proteína del ligando 1 de muerte celular programada (pd-l1).

Info

Publication number
MX2019002562A
MX2019002562A MX2019002562A MX2019002562A MX2019002562A MX 2019002562 A MX2019002562 A MX 2019002562A MX 2019002562 A MX2019002562 A MX 2019002562A MX 2019002562 A MX2019002562 A MX 2019002562A MX 2019002562 A MX2019002562 A MX 2019002562A
Authority
MX
Mexico
Prior art keywords
treating
methods
expressing cancer
cancer
paclitaxel
Prior art date
Application number
MX2019002562A
Other languages
English (en)
Inventor
N Markovic Svetomir
K Nevala Wendy
Original Assignee
Mayo Found Medical Education & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Found Medical Education & Res filed Critical Mayo Found Medical Education & Res
Publication of MX2019002562A publication Critical patent/MX2019002562A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En este documento se describen metodos, formulaciones y kits para tratar a un paciente con cancer con complejos de nanoparticulas que comprenden una proteina portadora, un agente de union y paclitaxel y, opcionalmente se tratan conjuntamente con un anticuerpo anti-PD-L1.
MX2019002562A 2016-09-06 2017-09-05 Métodos para tratar cáncer que expresa la proteína del ligando 1 de muerte celular programada (pd-l1). MX2019002562A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662383938P 2016-09-06 2016-09-06
PCT/US2017/050137 WO2018048816A1 (en) 2016-09-06 2017-09-05 Methods of treating pd-l1 expressing cancer

Publications (1)

Publication Number Publication Date
MX2019002562A true MX2019002562A (es) 2019-09-18

Family

ID=59901595

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019002562A MX2019002562A (es) 2016-09-06 2017-09-05 Métodos para tratar cáncer que expresa la proteína del ligando 1 de muerte celular programada (pd-l1).
MX2022005618A MX2022005618A (es) 2016-09-06 2019-03-05 Metodos para tratar cancer que expresa la proteina del ligando 1 de muerte celular programada (pd-l1).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022005618A MX2022005618A (es) 2016-09-06 2019-03-05 Metodos para tratar cancer que expresa la proteina del ligando 1 de muerte celular programada (pd-l1).

Country Status (10)

Country Link
US (3) US11427637B2 (es)
EP (1) EP3510048A1 (es)
JP (1) JP2019526587A (es)
KR (2) KR102486057B1 (es)
CN (1) CN109843924A (es)
AU (1) AU2017324335A1 (es)
CA (1) CA3035655A1 (es)
MX (2) MX2019002562A (es)
RU (1) RU2019110071A (es)
WO (1) WO2018048816A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2707030T3 (da) 2011-05-09 2020-05-18 Mayo Found Medical Education & Res Cancerbehandlinger
AU2013327638B2 (en) 2012-10-01 2018-06-14 Mayo Foundation For Medical Education And Research Cancer treatments
CN106573051B (zh) 2014-06-13 2021-07-13 梅约医药教育及研究基金会 治疗淋巴瘤
CN106604750B (zh) 2014-06-16 2021-05-07 梅约医学教育与研究基金会 治疗骨髓瘤
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
EP3399861A4 (en) 2016-01-07 2019-08-07 Mayo Foundation for Medical Education and Research METHOD FOR THE TREATMENT OF CANCER WITH INTERFERON
US11351254B2 (en) 2016-02-12 2022-06-07 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
WO2017165440A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
EP3432928A4 (en) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research PROCESS FOR IMPROVING THE THERAPEUTIC INDEX FOR CHEMOTHERAPEUTIC
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
EP4177271A1 (en) 2016-09-01 2023-05-10 Mayo Foundation for Medical Education and Research Carrier-pd-l1 binding agent compositions for treating cancers
US11160876B2 (en) 2016-09-01 2021-11-02 Mayo Foundation For Medical Education And Research Methods and compositions for targeting t-cell cancers
JP7025412B2 (ja) 2016-09-06 2022-02-24 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ パクリタキセル－アルブミン－結合剤組成物並びに該組成物の使用及び製造方法
US11590098B2 (en) 2016-09-06 2023-02-28 Mayo Foundation For Medical Education And Research Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
US20210023233A1 (en) * 2018-02-06 2021-01-28 Mayo Foundation For Medical Education And Research Antibody-peptide complexes and uses thereof
JP2022530674A (ja) * 2019-05-03 2022-06-30 ジェネンテック， インコーポレイテッド 抗ｐｄ－ｌ１抗体を用いたがんの処置方法
WO2022051414A1 (en) 2020-09-02 2022-03-10 Mayo Foundation For Medical Education And Research Antibody-nanoparticle complexes and methods for making and using the same

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4350687A (en) 1980-02-10 1982-09-21 Research Corporation Platelet derived cell growth factor
JPS60146833A (ja) 1984-01-10 1985-08-02 Green Cross Corp:The モノクロ−ナル抗体製剤
JPS6178731A (ja) 1985-05-20 1986-04-22 Green Cross Corp:The 加熱処理免疫グロブリン製剤
CA1327161C (en) 1987-09-01 1994-02-22 Mitsugu Kobayashi Lyophilized pharmaceutical composition of neocarzinostatin derivative
SE8801537D0 (sv) 1988-04-26 1988-04-26 Ellco Food Ab Cellodlingsmedium samt forfarande for dess framstellning
US5252713A (en) 1988-09-23 1993-10-12 Neorx Corporation Polymeric carriers for non-covalent drug conjugation
EP0465513A1 (en) 1989-03-27 1992-01-15 Centocor, Inc. FORMULATIONS FOR STABILIZING OF IgM ANTIBODIES
US5116944A (en) 1989-12-29 1992-05-26 Neorx Corporation Conjugates having improved characteristics for in vivo administration
US5216130A (en) 1990-05-17 1993-06-01 Albany Medical College Complex for in-vivo target localization
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5260308A (en) 1991-11-06 1993-11-09 Mayo Foundation For Medical Education And Research Method to increase permeability of the blood-nerve/brain barriers to proteins
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
WO1999000113A1 (en) 1997-06-27 1999-01-07 Vivorx Pharmaceuticals, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
ES2201296T3 (es) 1996-04-26 2004-03-16 Genaera Corporation Escualmina en combinacion con otros farmacos anticancerigenos para el tratamiento de tumores.
GB9613182D0 (en) 1996-06-24 1996-08-28 Nycomed Imaging As Method
US5728541A (en) 1996-07-12 1998-03-17 Precision Therapeutics, Inc. Method for preparing cell cultures from biologial specimens for chemotherapeutic and other assays
US6416967B2 (en) 1996-07-12 2002-07-09 Precision Therapeutics, Inc. Method of using multicellular particulates to analyze malignant or hyperproliferative tissue
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US7041301B1 (en) 1997-11-07 2006-05-09 Mayo Foundation For Medical Education And Research Interferon immunotherapy
US6616925B1 (en) 1998-04-02 2003-09-09 I.D.M. Immuno-Designed Molecules Combined preparation for the treatment of neoplasic diseases or of infectious diseases
US7112409B2 (en) 1999-01-29 2006-09-26 Center For Molecular Medicine And Immunology Method of determining cytokine dosage for myelosuppressive state
US7534866B2 (en) 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
JP2001072589A (ja) 1999-07-06 2001-03-21 Toagosei Co Ltd 制癌剤
US6420378B1 (en) 1999-10-15 2002-07-16 Supergen, Inc. Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
DE10132502A1 (de) 2001-07-05 2003-01-23 Gsf Forschungszentrum Umwelt Angriff auf Tumorzellen mit fehlender, niedriger oder anormaler MHC-Expression durch kombinieren von nicht MHC-Restringierten T-Zellen/NK-Zellen und MHC-Restringierten Zellen
CN1652820A (zh) 2002-04-12 2005-08-10 梅达雷克斯公司 使用ctla－4抗体的治疗方法
AU2003265264A1 (en) 2002-07-09 2004-01-23 Point Therapeutics, Inc. Methods and compositions relating to isoleucine boroproline compounds
EP1539234A4 (en) 2002-09-05 2006-02-15 Medimmune Inc METHOD FOR PREVENTING OR TREATING CELL MALIGNITY BY ADMINISTERING CD2 ANTAGONISTS
AU2003265948B8 (en) 2002-09-06 2009-09-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
EP1585548B1 (en) 2002-12-09 2018-06-27 Abraxis BioScience, LLC Compositions and methods of delivery of pharmacological agents
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
AR046510A1 (es) 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
DE602004025834D1 (de) 2003-10-22 2010-04-15 Univ Johns Hopkins Die behandlung von tumoren
EP1763356B1 (en) 2004-04-22 2008-07-16 Eli Lilly And Company Composition comprising a survivin antisense oligonucleotide and gemcitabine for the treatment of cancer
AU2005286662B2 (en) 2004-09-23 2011-10-06 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
EP1812864A2 (en) 2004-10-07 2007-08-01 Emory University Multifunctional nanoparticles conjugates and their use
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US20070166388A1 (en) 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
KR101976003B1 (ko) 2005-02-18 2019-05-09 아브락시스 바이오사이언스, 엘엘씨 치료제의 조합 및 투여 방식, 및 조합 요법
US7976852B2 (en) 2005-04-26 2011-07-12 Eisai R&D Management Co., Ltd. Compositions and methods for cancer immunotherapy
US10183076B2 (en) 2005-05-16 2019-01-22 Resdevco Research And Development Co. L Topical compositions for treatment of irritation of mucous membranes
ES2784794T3 (es) 2005-08-31 2020-10-01 Abraxis Bioscience Llc Composiciones que comprenden agentes farmacéuticos poco solubles en agua y agentes antimicrobianos
US8034765B2 (en) 2005-08-31 2011-10-11 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
US7776832B2 (en) 2006-04-21 2010-08-17 Gem Pharmaceuticals, Llc Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines
AU2007302448C1 (en) 2006-09-26 2019-02-14 Genmab A/S Combination treatment of CD38-expressing tumors
EP2081687A2 (en) 2006-10-17 2009-07-29 Koninklijke Philips Electronics N.V. Device for amplification and detection of nucleic acids
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
GB0621973D0 (en) 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
US20100112077A1 (en) 2006-11-06 2010-05-06 Abraxis Bioscience, Llc Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
MX2009004829A (es) 2006-11-07 2009-07-24 Dow Agrosciences Llc Formulacion para tecnica de aniquilacion de machos (mat) para rociar, con liberacion controlada, y metodo de control de insectos.
CA2672828A1 (en) 2006-12-13 2008-06-26 Schering Corporation Methods of treatment
ES2700074T3 (es) 2006-12-14 2019-02-13 Abraxis Bioscience Llc Terapia para el cáncer de mama sobre la base del estado de los receptores hormonales con nanopartículas que comprenden taxano
EP2481409B1 (en) 2007-03-07 2018-05-09 Abraxis BioScience, LLC Nanoparticle comprising rapamycin and albumin as anticancer agent
WO2008112987A1 (en) 2007-03-14 2008-09-18 Mayo Foundation For Medical Education And Research Treating skin cancer
WO2009005673A1 (en) 2007-06-28 2009-01-08 Schering Corporation Anti-igf1r
CA2700457A1 (en) 2007-10-01 2009-04-09 Austin Smith Neural tumor stem cells and methods of use thereof
CN101918579A (zh) 2007-10-22 2010-12-15 先灵公司 完全人抗-vegf抗体和使用方法
US8034905B2 (en) 2007-11-09 2011-10-11 Affitech Research, AS Anti-VEGF antibody compositions and methods
EP3266453A1 (en) 2008-07-03 2018-01-10 Mayo Foundation for Medical Education and Research Treating cancer
KR20110051214A (ko) 2008-07-30 2011-05-17 닛토덴코 가부시키가이샤 약물 담체
US8119129B2 (en) 2008-08-01 2012-02-21 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
AU2009279736A1 (en) 2008-08-04 2010-02-11 Allocure, Inc. Mesenchymal stromal cell populations and methods of isolating and using same
WO2010075540A1 (en) 2008-12-23 2010-07-01 Burnham Institute For Medical Research Methods and compositions for synaphically-targeted treatment for cancer
US20100189651A1 (en) 2009-01-12 2010-07-29 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
US9636384B2 (en) 2009-04-06 2017-05-02 Mayo Foundation For Medical Education And Research Methods for making polymeric nanoparticle-polypeptide complex
BRPI1014160A2 (pt) 2009-04-10 2015-08-25 Abraxis Bioscience Llc Formulações de nanopartículas e aplicações das mesmas
US8571805B2 (en) 2009-04-10 2013-10-29 Pharmaco-Kinesis Corporation Method and apparatus for detecting and regulating vascular endothelial growth factor (VEGF) by forming a homeostatic loop employing a half-antibody biosensor
WO2010124009A2 (en) 2009-04-21 2010-10-28 Schering Corporation Fully human anti-vegf antibodies and methods of using
AU2010251966A1 (en) 2009-05-28 2011-12-22 Glaxo Group Limited Combination of a TNF-alpha antagonist and a VEGF antagonist for use in the treatment or prevention of diseases of the eye.
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
WO2011057099A2 (en) 2009-11-05 2011-05-12 The Uab Research Foundation Treating basal-like genotype cancers
BR112012011268A2 (pt) 2009-11-13 2019-09-24 Merck Patent Gmbh anticorpos anti-integrina ligados a nanopartículas carregadas com agentes quimioterapêuticos
SG10201504590WA (en) 2010-06-07 2015-07-30 Abraxis Bioscience Llc Combination Therapy Methods For Treating Proliferative Diseases
EP2625525A4 (en) 2010-10-08 2014-04-02 Abraxis Bioscience Llc SPARC MICRO ENVIRONMENT SIGNATURE, PLASMA SPARC AND LDH AS PROGNOSTIC BIOMARKERS IN THE TREATMENT OF CANCER
US20130281377A1 (en) 2010-12-23 2013-10-24 Mayo Foundation For Medical Education And Research Treating multiple myeloma
US20120283290A1 (en) 2011-05-06 2012-11-08 Amicus Therapeutics Inc. Quantitation of gl3 in urine
DK2707030T3 (da) * 2011-05-09 2020-05-18 Mayo Found Medical Education & Res Cancerbehandlinger
US20130028895A1 (en) 2011-07-27 2013-01-31 Gerald Wulf Exosome inhibiting agents and uses thereof
WO2013043569A1 (en) 2011-09-20 2013-03-28 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
EP2768425B1 (en) 2011-10-17 2018-11-14 University of Utah Research Foundation Methods and devices for connecting nerves
EP2788377B1 (en) 2011-11-09 2019-01-23 The UAB Research Foundation Her3 antibodies and uses thereof
ES2939836T3 (es) 2012-07-12 2023-04-27 Hangzhou Dac Biotech Co Ltd Conjugados de moléculas de unión celular con agentes citotóxicos
EP2893003B1 (en) 2012-09-04 2021-03-31 Inven2 AS Selective and controlled expansion of educated nk cells
AU2013327638B2 (en) 2012-10-01 2018-06-14 Mayo Foundation For Medical Education And Research Cancer treatments
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
US20140186447A1 (en) 2012-12-28 2014-07-03 Abraxis Bioscience, Llc Nanoparticle compositions of albumin and paclitaxel
HK1218506A1 (zh) 2013-02-11 2017-02-24 阿布拉科斯生物科学有限公司 治療黑素瘤的方法
AU2014324703C1 (en) * 2013-09-27 2020-10-29 Genentech, Inc. Anti-PDL1 antibody formulations
SG11201604956SA (en) * 2013-12-17 2016-07-28 Genentech Inc Methods of treating cancers using pd-1 axis binding antagonists and taxanes
US10232040B2 (en) * 2014-05-13 2019-03-19 Medimmune, Llc Anti-B7 H1 and anti-CTLA-4 antibodies for treating non-small cell lung cancer
CN106573051B (zh) 2014-06-13 2021-07-13 梅约医药教育及研究基金会 治疗淋巴瘤
CN106604750B (zh) 2014-06-16 2021-05-07 梅约医学教育与研究基金会 治疗骨髓瘤
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
BR112016030965A2 (pt) 2014-10-06 2017-08-22 Mayo Found Medical Education & Res Composições de veículo-anticorpo e métodos de fabricação e uso das mesmas
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
JP2018501218A (ja) * 2014-12-02 2018-01-18 セルジーン コーポレイション 併用療法
GB201500374D0 (en) * 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
US20180155429A1 (en) * 2015-05-28 2018-06-07 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
WO2017176265A1 (en) 2016-04-06 2017-10-12 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
EP3337823A4 (en) 2015-08-18 2019-05-08 Mayo Foundation for Medical Education and Research SUPPORTING BIN COMPOSITIONS AND METHOD FOR THE PRODUCTION AND USE THEREOF
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
EP3399861A4 (en) 2016-01-07 2019-08-07 Mayo Foundation for Medical Education and Research METHOD FOR THE TREATMENT OF CANCER WITH INTERFERON
US11351254B2 (en) 2016-02-12 2022-06-07 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
WO2017165440A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
EP3432928A4 (en) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research PROCESS FOR IMPROVING THE THERAPEUTIC INDEX FOR CHEMOTHERAPEUTIC
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
KR20230006037A (ko) 2016-08-05 2023-01-10 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 암 치료를 위한 변형된 항체-알부민 나노입자 복합체
EP4177271A1 (en) 2016-09-01 2023-05-10 Mayo Foundation for Medical Education and Research Carrier-pd-l1 binding agent compositions for treating cancers
US11160876B2 (en) 2016-09-01 2021-11-02 Mayo Foundation For Medical Education And Research Methods and compositions for targeting t-cell cancers
JP7025412B2 (ja) 2016-09-06 2022-02-24 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ パクリタキセル－アルブミン－結合剤組成物並びに該組成物の使用及び製造方法
MX2019002626A (es) 2016-09-06 2019-10-02 Walmart Apollo Llc Selector de imagenes de una pieza de un producto.
US11590098B2 (en) 2016-09-06 2023-02-28 Mayo Foundation For Medical Education And Research Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
CA3080406A1 (en) 2016-10-28 2018-05-03 Nrl Pharma, Inc. Lactoferrin/albumin fusion protein and production method thereof

Also Published As

Publication number Publication date
CN109843924A (zh) 2019-06-04
US20210130469A1 (en) 2021-05-06
MX2022005618A (es) 2022-06-23
EP3510048A1 (en) 2019-07-17
WO2018048816A1 (en) 2018-03-15
JP2019526587A (ja) 2019-09-19
AU2017324335A1 (en) 2019-03-28
US11427637B2 (en) 2022-08-30
US20220363765A1 (en) 2022-11-17
RU2019110071A (ru) 2020-10-08
US20260001955A1 (en) 2026-01-01
KR20230011473A (ko) 2023-01-20
CA3035655A1 (en) 2018-03-15
KR102486057B1 (ko) 2023-01-10
KR20190052682A (ko) 2019-05-16

Similar Documents

Publication Publication Date Title
MX2019002562A (es) Métodos para tratar cáncer que expresa la proteína del ligando 1 de muerte celular programada (pd-l1).
TW201713360A (en) Methods of treating cancer using compositions of antibodies and carrier proteins
MX2019001517A (es) Complejos de nanopartículas de albúmina modificada con anticuerpos para el tratamiento del cáncer.
MX2019002474A (es) Composiciones de agente de unión de portador-ligando-1 de muerte programada y métodos de uso de las mismas para el tratamiento de cánceres.
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
MY186711A (en) Igf-1r antibody-drug-conjugate and its use for the treatment of cancer
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
AU2017228470A8 (en) Combination therapy with anti-CD73 antibodies
MX2019002564A (es) Composiciones de agente de unión de albúmina-paclitaxel y métodos de uso y elaboración de las mismas.
CY1119799T1 (el) Συνδυασμος αντισωματων anti-kir και αντισωματων anti-pd-1 για αγωγη καρκινου
WO2019234241A8 (en) ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT
PH12016501384A1 (en) Human antibodies to pd-l1
ZA201708265B (en) Tigit-binding agents and uses thereof
EA201792191A1 (ru) Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли
BR112016013896A2 (pt) métodos de tratamento de câncer positivo para her2 usando antagonistas de ligação do eixo de pd-1 e anticorpos anti-her2
MX375221B (es) Composiciones que comprenden anticuerpos anti-molécula de adhesión celular relacionada con antígeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cáncer.
MX2017004526A (es) Terapia combinada de anticuerpos biespecificos especificos para fap y dr5 y agentes quimioterapeuticos.
CO2017001023A2 (es) Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas
NZ739499A (en) Single domain antibody for programmed death-ligand (pd-l1) and derived protein thereof
SG10201906471PA (en) Treatment of cancer with anti-lap monoclonal antibodies
PH12017500406A1 (en) Novel anti-mfi2 antibodies and methods of use
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
MX2019015604A (es) Anticuerpos anti-tau y usos de los mismos en el tratamiento de una tauopatia.
MX2021005236A (es) Regimen de dosificacion de anticuerpo anti-tigit para el tratamiento de cancer.
CR20200623A (es) Conjugados de fármaco y anticuerpo anti-sez6 y métodos de uso